Filtered By:
Cancer: Liver Cancer
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 31222 results found since Jan 2013.
Role of organic cation transporter 3 (OCT3) in the response of hepatocellular carcinoma to tyrosine kinase inhibitors
In conclusion, analysis by immunohistochemistry of OCT3 in the PM of tumor cells may help to predict the response of HCC patients to sorafenib and potentially to other TKIs.PMID:37722628 | DOI:10.1016/j.bcp.2023.115812
Source: Biochemical Pharmacology - September 18, 2023 Category: Drugs & Pharmacology Authors: Elisa Herraez Ruba Al-Abdulla Meraris Soto Oscar Briz Dominik Bettinger Heike Bantel Sofia Del Carmen Maria A Serrano Andreas Geier Jose J G Marin Rocio I R Macias Source Type: research
Assessing the prognostic value of IMDC risk score for nivolumab-treated patients with renal cancer and malignant melanoma
CONCLUSION: In our study, the IMDC was confirmed to be a prognostic factor for MM. The IMDC groups were similar, except for the favorable RCC and MM groups. Different metastatic sites were prognostic, similar to the IMDC risk group in the MM group.PMID:37718781 | DOI:10.3233/CBM-230159
Source: Cancer Biomarkers : Section A of Disease Markers - September 18, 2023 Category: Cancer & Oncology Authors: Ismail Beyp ınar Y ıldız Sözel Arif Hakan Önder Source Type: research
CRISPR/Cas9-mediated deletion of adipocyte genes associated with NAFLD alters adipocyte lipid handling and reduces steatosis in hepatocytes < em > in vitro < /em >
Am J Physiol Cell Physiol. 2023 Sep 18. doi: 10.1152/ajpcell.00291.2023. Online ahead of print.ABSTRACTObesity is a major risk factor for the development of non-alcoholic fatty liver disease (NAFLD) and the subcutaneous white adipose tissue (scWAT) is the primary lipid storage depot and regulates lipid fluxes to other organs. Our previous work identified genes up-regulated in scWAT of patients with NAFLD: SOCS3, DUSP1, and SIK1. Herein, we knocked down (KD) their expression in human adipose-derived mesenchymal stem cells (hADMSCs) using CRISPR/Cas9 technology and characterized their phenotype. We found that SOCS3, DUSP1, a...
Source: Am J Physiol Cell Ph... - September 18, 2023 Category: Cytology Authors: Marta Lopez-Yus Scott Frendo-Cumbo Raquel Del Moral-Bergos Maria Pilar Garcia-Sobreviela Vanesa Bernal-Monterde Mikael Ryd én Silvia Lorente-Cebrian Jose M Arbones-Mainar Source Type: research
Role of organic cation transporter 3 (OCT3) in the response of hepatocellular carcinoma to tyrosine kinase inhibitors
In conclusion, analysis by immunohistochemistry of OCT3 in the PM of tumor cells may help to predict the response of HCC patients to sorafenib and potentially to other TKIs.PMID:37722628 | DOI:10.1016/j.bcp.2023.115812
Source: Biochemical Pharmacology - September 18, 2023 Category: Drugs & Pharmacology Authors: Elisa Herraez Ruba Al-Abdulla Meraris Soto Oscar Briz Dominik Bettinger Heike Bantel Sofia Del Carmen Maria A Serrano Andreas Geier Jose J G Marin Rocio I R Macias Source Type: research
CRISPR/Cas9-mediated deletion of adipocyte genes associated with NAFLD alters adipocyte lipid handling and reduces steatosis in hepatocytes < em > in vitro < /em >
Am J Physiol Cell Physiol. 2023 Sep 18. doi: 10.1152/ajpcell.00291.2023. Online ahead of print.ABSTRACTObesity is a major risk factor for the development of non-alcoholic fatty liver disease (NAFLD) and the subcutaneous white adipose tissue (scWAT) is the primary lipid storage depot and regulates lipid fluxes to other organs. Our previous work identified genes up-regulated in scWAT of patients with NAFLD: SOCS3, DUSP1, and SIK1. Herein, we knocked down (KD) their expression in human adipose-derived mesenchymal stem cells (hADMSCs) using CRISPR/Cas9 technology and characterized their phenotype. We found that SOCS3, DUSP1, a...
Source: Am J Physiol Cell Ph... - September 18, 2023 Category: Cytology Authors: Marta Lopez-Yus Scott Frendo-Cumbo Raquel Del Moral-Bergos Maria Pilar Garcia-Sobreviela Vanesa Bernal-Monterde Mikael Ryd én Silvia Lorente-Cebrian Jose M Arbones-Mainar Source Type: research
Assessing the prognostic value of IMDC risk score for nivolumab-treated patients with renal cancer and malignant melanoma
CONCLUSION: In our study, the IMDC was confirmed to be a prognostic factor for MM. The IMDC groups were similar, except for the favorable RCC and MM groups. Different metastatic sites were prognostic, similar to the IMDC risk group in the MM group.PMID:37718781 | DOI:10.3233/CBM-230159
Source: Cancer Biomarkers : Section A of Disease Markers - September 18, 2023 Category: Cancer & Oncology Authors: Ismail Beyp ınar Y ıldız Sözel Arif Hakan Önder Source Type: research
HSP90 C-terminal domain inhibition promotes VDAC1 oligomerization via decreasing K274 mono-ubiquitination in Hepatocellular Carcinoma
In this study, we focused on the effect of the C-terminal domain of Hsp90 on VDAC1 oligomerization, ubiquitination, and VDAC1 channel activity. We found that Hsp90 C-terminal domain inhibitor Novobiocin promoted VDAC1 oligomerization, release of cytochrome c, and activated mitochondrial apoptosis pathway. Atomic coarse particle modeling simulation revealed C-terminal domain of Hsp90α stabilized VDAC1 monomers. The purified VDAC1 was reconstituted into a planar lipid bilayer, and electrophysiology experiments of patch clamp showed that the Hsp90 C-terminal inhibitor Novobiocin increased VDAC1 channel conductance via promot...
Source: Neoplasia - September 17, 2023 Category: Cancer & Oncology Authors: Jinxin Zhang Lixia Liu Yan Li Yaling Huang Senbo Xiao Zihao Deng Zhenming Zheng Jieyou Li Manfeng Liang Guantai Xie Xiao Chen Yaotang Deng Wenchong Tan Hairou Su Guibing Wu Chunqing Cai Xuemei Chen Fei Zou Source Type: research
MAIT cells confer resistance to Lenvatinib plus anti-PD1 antibodies in hepatocellular carcinoma through TNF-TNFRSF1B pathway
Clin Immunol. 2023 Sep 15:109770. doi: 10.1016/j.clim.2023.109770. Online ahead of print.ABSTRACTThe combination of antiangiogenic agents and immune checkpoint inhibitors is more efficient than monotherapy in the management of hepatocellular carcinoma (HCC). Lenvatinib plus anti-PD1 antibodies have become the mainstay in HCC treatment. However, more than half the patients with HCC are non-responsive, and the mechanisms underlying drug resistance are unknown. To address this issue, we performed single-cell sequencing on samples from six HCC patients, aiming to explore cellular signals and molecular pathways related to the e...
Source: Clinical Immunology - September 17, 2023 Category: Allergy & Immunology Authors: Cheng Zhou Bao-Ye Sun Pei-Yun Zhou Zhang-Fu Yang Zhu-Tao Wang Gao Liu Wei Gan Zheng Wang Jian Zhou Jia Fan Yong Yi Ning Ren Shuang-Jian Qiu Source Type: research
HSP90 C-terminal domain inhibition promotes VDAC1 oligomerization via decreasing K274 mono-ubiquitination in Hepatocellular Carcinoma
In this study, we focused on the effect of the C-terminal domain of Hsp90 on VDAC1 oligomerization, ubiquitination, and VDAC1 channel activity. We found that Hsp90 C-terminal domain inhibitor Novobiocin promoted VDAC1 oligomerization, release of cytochrome c, and activated mitochondrial apoptosis pathway. Atomic coarse particle modeling simulation revealed C-terminal domain of Hsp90α stabilized VDAC1 monomers. The purified VDAC1 was reconstituted into a planar lipid bilayer, and electrophysiology experiments of patch clamp showed that the Hsp90 C-terminal inhibitor Novobiocin increased VDAC1 channel conductance via promot...
Source: Neoplasia - September 17, 2023 Category: Cancer & Oncology Authors: Jinxin Zhang Lixia Liu Yan Li Yaling Huang Senbo Xiao Zihao Deng Zhenming Zheng Jieyou Li Manfeng Liang Guantai Xie Xiao Chen Yaotang Deng Wenchong Tan Hairou Su Guibing Wu Chunqing Cai Xuemei Chen Fei Zou Source Type: research
Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study
CONCLUSIONS: Compared with Atez/Bev treatment, TACE-Atez/Bev showed better OS, PFS, and ORR for Chinese patients with advanced HCC, with an acceptable safety profile.PMID:37718456 | DOI:10.1186/s12885-023-11389-x
Source: Cancer Control - September 17, 2023 Category: Cancer & Oncology Authors: Fei Cao Changsheng Shi Guofu Zhang Jun Luo Jiaping Zheng Weiyuan Hao Source Type: research
HSP90 C-terminal domain inhibition promotes VDAC1 oligomerization via decreasing K274 mono-ubiquitination in Hepatocellular Carcinoma
In this study, we focused on the effect of the C-terminal domain of Hsp90 on VDAC1 oligomerization, ubiquitination, and VDAC1 channel activity. We found that Hsp90 C-terminal domain inhibitor Novobiocin promoted VDAC1 oligomerization, release of cytochrome c, and activated mitochondrial apoptosis pathway. Atomic coarse particle modeling simulation revealed C-terminal domain of Hsp90α stabilized VDAC1 monomers. The purified VDAC1 was reconstituted into a planar lipid bilayer, and electrophysiology experiments of patch clamp showed that the Hsp90 C-terminal inhibitor Novobiocin increased VDAC1 channel conductance via promot...
Source: Neoplasia - September 17, 2023 Category: Cancer & Oncology Authors: Jinxin Zhang Lixia Liu Yan Li Yaling Huang Senbo Xiao Zihao Deng Zhenming Zheng Jieyou Li Manfeng Liang Guantai Xie Xiao Chen Yaotang Deng Wenchong Tan Hairou Su Guibing Wu Chunqing Cai Xuemei Chen Fei Zou Source Type: research
MAIT cells confer resistance to Lenvatinib plus anti-PD1 antibodies in hepatocellular carcinoma through TNF-TNFRSF1B pathway
Clin Immunol. 2023 Sep 15:109770. doi: 10.1016/j.clim.2023.109770. Online ahead of print.ABSTRACTThe combination of antiangiogenic agents and immune checkpoint inhibitors is more efficient than monotherapy in the management of hepatocellular carcinoma (HCC). Lenvatinib plus anti-PD1 antibodies have become the mainstay in HCC treatment. However, more than half the patients with HCC are non-responsive, and the mechanisms underlying drug resistance are unknown. To address this issue, we performed single-cell sequencing on samples from six HCC patients, aiming to explore cellular signals and molecular pathways related to the e...
Source: Clinical Immunology - September 17, 2023 Category: Allergy & Immunology Authors: Cheng Zhou Bao-Ye Sun Pei-Yun Zhou Zhang-Fu Yang Zhu-Tao Wang Gao Liu Wei Gan Zheng Wang Jian Zhou Jia Fan Yong Yi Ning Ren Shuang-Jian Qiu Source Type: research
